165 related articles for article (PubMed ID: 590311)
1. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
Casals-Stenzel J; Schmalbach J; Losert W
Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
[TBL] [Abstract][Full Text] [Related]
2. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
Casals-Stenzel J; Buse M; Losert W
Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
[TBL] [Abstract][Full Text] [Related]
3. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical potassium excretion in response to aldosterone antagonists.
Ramsay LE; Harrison IR; Shelton JR; Tidd MJ
Eur J Clin Pharmacol; 1977 Jan; 11(2):101-5. PubMed ID: 837961
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone and potassium canrenoate in normal man.
Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone and canrenoate-K: relative potency at steady state.
Ramsay L; Asbury M; Shelton J; Harrison I
Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
[TBL] [Abstract][Full Text] [Related]
7. Effect of aldosterone on potassium excretion during potassium chloride infusion in sheep.
Rabinowitz L; Sarason RL; Yamauchi H
Am J Physiol; 1985 Oct; 249(4 Pt 2):R455-61. PubMed ID: 4051031
[TBL] [Abstract][Full Text] [Related]
8. Relative potency of prorenoate and spironolactone in normal man.
Ramsay L; Harrison I; Shelton J; Tidd M
Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
[TBL] [Abstract][Full Text] [Related]
10. Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.
Sorrentino R; Autore G; Cirino G; d'Emmanuele de Villa Bianca R; Calignano A; Vanasia M; Alfieri C; Sorrentino L; Pinto A
J Cardiovasc Pharmacol; 2000 Aug; 36(2):230-5. PubMed ID: 10942165
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
Levine D; Ramsay L; Auty R; Branch R; Tidd M
Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
[TBL] [Abstract][Full Text] [Related]
12. Sheep renal potassium excretion: efferent kaliuretic regulatory factors.
Rabinowitz L; Sarason RL; Yamauchi H
Am J Physiol; 1984 Sep; 247(3 Pt 2):F520-6. PubMed ID: 6476127
[TBL] [Abstract][Full Text] [Related]
13. Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.
Gudmundsson FF; Viste A; Myking OL; Grong K; Svanes K
Surg Endosc; 2004 Oct; 18(10):1528-34. PubMed ID: 15791383
[TBL] [Abstract][Full Text] [Related]
14. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
Dasgupta A; Johnson MJ
J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
Dasgupta A; Saffer H; Wells A; Datta P
J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
[TBL] [Abstract][Full Text] [Related]
16. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
[TBL] [Abstract][Full Text] [Related]
17. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
18. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans.
van Buren M; Boer P; Koomans HA
J Clin Endocrinol Metab; 1993 Oct; 77(4):902-9. PubMed ID: 8408463
[TBL] [Abstract][Full Text] [Related]
19. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
[TBL] [Abstract][Full Text] [Related]
20. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
McInnes GT; Shelton JR; Harrison IR
Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
